Steven J Skates

Summary

Affiliation: Massachusetts General Hospital
Country: USA

Publications

  1. ncbi Screening for ovarian cancer-risk, education, worry: path to appropriate use?
    Steven J Skates
    Gynecol Oncol 85:1-2. 2002
  2. ncbi Impact on mortality and cancer incidence rates of using random invitation from population registers for recruitment to trials
    Matthew Burnell
    Gynaecological Oncology, EGA Institute for Women s Health, University College London, London, UK
    Trials 12:61. 2011
  3. ncbi Preoperative sensitivity and specificity for early-stage ovarian cancer when combining cancer antigen CA-125II, CA 15-3, CA 72-4, and macrophage colony-stimulating factor using mixtures of multivariate normal distributions
    Steven J Skates
    Massachusetts General Hospital, 50 Stanford St, Suite 560, Boston, MA 02114, USA
    J Clin Oncol 22:4059-66. 2004
  4. ncbi Longitudinal CA125 detection of sporadic papillary serous carcinoma of the peritoneum
    S Skates
    MGH Biostatistics Center, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, USA
    Int J Gynecol Cancer 13:693-6. 2003
  5. ncbi Calculation of the risk of ovarian cancer from serial CA-125 values for preclinical detection in postmenopausal women
    Steven J Skates
    Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA
    J Clin Oncol 21:206s-210s. 2003
  6. ncbi Identification of epithelial cell adhesion molecule autoantibody in patients with ovarian cancer
    Jae-hoon Kim
    Department of Obstetrics, Gynecology and Reproductive Biology, Division of Gynecologic Oncology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
    Clin Cancer Res 9:4782-91. 2003
  7. ncbi Haptoglobin-alpha subunit as potential serum biomarker in ovarian cancer: identification and characterization using proteomic profiling and mass spectrometry
    Bin Ye
    Department of Obstetrics and Gynecology, Brigham and Women s Hospital, Dana Farber Cancer Institute, Dana Farber Harvard Cancer Center, Boston, MA 02115, USA
    Clin Cancer Res 9:2904-11. 2003
  8. ncbi Pooling of case specimens to create standard serum sets for screening cancer biomarkers
    Steven J Skates
    Biostatistics Center, Massachusetts General Hospital, Boston, USA
    Cancer Epidemiol Biomarkers Prev 16:334-41. 2007
  9. ncbi Blood and urine markers for ovarian cancer: a comprehensive review
    Kathryn L Terry
    Ob-Gyn Center Epidemiology Center, Department of Obstetrics, Gynecology, and Reproductive Biology, Brigham and Women's Hospital, Boston, MA, USA
    Dis Markers 20:53-70. 2004
  10. ncbi Ovarian cancer biomarker performance in prostate, lung, colorectal, and ovarian cancer screening trial specimens
    Daniel W Cramer
    Brigham and Women s Hospital, Ob Gyn, Division of Epidemiology, Boston, MA 02115, USA
    Cancer Prev Res (Phila) 4:365-74. 2011

Detail Information

Publications19

  1. ncbi Screening for ovarian cancer-risk, education, worry: path to appropriate use?
    Steven J Skates
    Gynecol Oncol 85:1-2. 2002
  2. ncbi Impact on mortality and cancer incidence rates of using random invitation from population registers for recruitment to trials
    Matthew Burnell
    Gynaecological Oncology, EGA Institute for Women s Health, University College London, London, UK
    Trials 12:61. 2011
    ..This report assesses the extent of the HVE still prevalent in UKCTOCS and considers how certain shortfalls in mortality and incidence can be related to differences in socioeconomic status...
  3. ncbi Preoperative sensitivity and specificity for early-stage ovarian cancer when combining cancer antigen CA-125II, CA 15-3, CA 72-4, and macrophage colony-stimulating factor using mixtures of multivariate normal distributions
    Steven J Skates
    Massachusetts General Hospital, 50 Stanford St, Suite 560, Boston, MA 02114, USA
    J Clin Oncol 22:4059-66. 2004
    ..For direct comparisons between marker panels, all sensitivity results correspond to a 98% fixed first-line specificity (referral rate 2%)...
  4. ncbi Longitudinal CA125 detection of sporadic papillary serous carcinoma of the peritoneum
    S Skates
    MGH Biostatistics Center, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, USA
    Int J Gynecol Cancer 13:693-6. 2003
    ..This rare primary tumor is usually associated with women at high risk for epithelial ovarian carcinoma, although this patient was not at high risk as she had no familial breast or ovarian cancer history...
  5. ncbi Calculation of the risk of ovarian cancer from serial CA-125 values for preclinical detection in postmenopausal women
    Steven J Skates
    Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA
    J Clin Oncol 21:206s-210s. 2003
    ..We conducted a study to assess the screening performance of the risk of ovarian cancer calculation based on serial CA-125 levels from prospectively collected serum samples compared with a fixed CA-125 cutoff...
  6. ncbi Identification of epithelial cell adhesion molecule autoantibody in patients with ovarian cancer
    Jae-hoon Kim
    Department of Obstetrics, Gynecology and Reproductive Biology, Division of Gynecologic Oncology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
    Clin Cancer Res 9:4782-91. 2003
    ..090 in 26 normal women. This investigation has shown that the Ep-CAM autoantibody was found to be associated with ovarian cancer and suggested that future research assessing its clinical usefulness would be worthwhile...
  7. ncbi Haptoglobin-alpha subunit as potential serum biomarker in ovarian cancer: identification and characterization using proteomic profiling and mass spectrometry
    Bin Ye
    Department of Obstetrics and Gynecology, Brigham and Women s Hospital, Dana Farber Cancer Institute, Dana Farber Harvard Cancer Center, Boston, MA 02115, USA
    Clin Cancer Res 9:2904-11. 2003
    ..An antibody was generated from the synthesized peptide for quantitative validation in the cases and controls. CA125 was determined and compared with the same set of specimens...
  8. ncbi Pooling of case specimens to create standard serum sets for screening cancer biomarkers
    Steven J Skates
    Biostatistics Center, Massachusetts General Hospital, Boston, USA
    Cancer Epidemiol Biomarkers Prev 16:334-41. 2007
    ..We describe the creation and use of standard serum sets developed from healthy donors and pooled sera from ovarian, breast, and endometrial cancer cases...
  9. ncbi Blood and urine markers for ovarian cancer: a comprehensive review
    Kathryn L Terry
    Ob-Gyn Center Epidemiology Center, Department of Obstetrics, Gynecology, and Reproductive Biology, Brigham and Women's Hospital, Boston, MA, USA
    Dis Markers 20:53-70. 2004
  10. ncbi Ovarian cancer biomarker performance in prostate, lung, colorectal, and ovarian cancer screening trial specimens
    Daniel W Cramer
    Brigham and Women s Hospital, Ob Gyn, Division of Epidemiology, Boston, MA 02115, USA
    Cancer Prev Res (Phila) 4:365-74. 2011
    ..Despite many promising new markers for ovarian cancer, CA125 remains the single-best biomarker in the phase II and phase III specimens tested in this study...
  11. ncbi Progress in the management of gynecologic cancer: consensus summary statement
    Stephen A Cannistra
    Department of Gynecologic Medical Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Brigham and Women's Hospital, Dana-Farber Cancer Institute, and Massachusetts General Hospital, Boston, USA
    J Clin Oncol 21:129s-132s. 2003
  12. ncbi Large prospective study of ovarian cancer screening in high-risk women: CA125 cut-point defined by menopausal status
    Steven J Skates
    Biostatistics Center, Massachusetts General Hospital, Boston, MA 02114, USA
    Cancer Prev Res (Phila) 4:1401-8. 2011
    ....
  13. ncbi Ovarian cancer screening: development of the risk of ovarian cancer algorithm (ROCA) and ROCA screening trials
    Steven J Skates
    Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
    Int J Gynecol Cancer 22:S24-6. 2012
    ..Subsequent screening trials implemented the risk of ovarian cancer algorithm (ROCA) in which screening decisions are made based on the risk of having a change point. Development of ROCA is described, and ROCA trials are listed...
  14. ncbi Expression of multidrug resistance-1 protein inversely correlates with paclitaxel response and survival in ovarian cancer patients: a study in serial samples
    Richard T Penson
    Division of Hematology/Oncology, Massachusetts General Hospital, Boston, MA 02114, USA
    Gynecol Oncol 93:98-106. 2004
    ..However, P-gp over-expression is a significant prognostic factor, and at the time of disease, relapse is inversely correlated with tumor response to paclitaxel...
  15. ncbi Osteopontin as a potential diagnostic biomarker for ovarian cancer
    Jae Hoon Kim
    Laboratory of Gynecologic Oncology, Division of Gynecologic Oncology, Department of Obstetrics, Gynecology, and Reproductive Biology, Brigham and Women s Hospital, Boston, MA 02115, USA
    JAMA 287:1671-9. 2002
    ..Analyses involving complementary DNA (cDNA) microarray data can be used to identify up-regulated genes in cancer cells, whose products may then be further validated as potential biomarkers...
  16. ncbi Prospective study using the risk of ovarian cancer algorithm to screen for ovarian cancer
    Usha Menon
    Department of Gynecological Oncology, Institute of Women's Health, University College London
    J Clin Oncol 23:7919-26. 2005
    ..It is being used in the United Kingdom Collaborative Trial of Ovarian Cancer Screening and in the United States in both the Cancer Genetics Network and the Gynecology Oncology Group trials of high-risk women...
  17. ncbi Combined CA125 and mesothelin levels for the diagnosis of malignant mesothelioma
    Jenette Creaney
    National Research Centre for Asbestos Related Diseases, 4th Floor, G Block, Sir Charles Gairdner Hospital, Verdun St, Nedlands, WA 6009, Australia
    Chest 132:1239-46. 2007
    ..The purpose of this study was to study the mesothelin biomarker in a large patient cohort and to determine if another biomarker, CA125, improves on the sensitivity of mesothelin in the diagnosis of mesothelioma...
  18. ncbi Cancer yield of mammography, MR, and US in high-risk women: prospective multi-institution breast cancer screening study
    Constance D Lehman
    Department of Radiology, University of Washington Medical Center, Seattle Cancer Care Alliance, 825 Eastlake Ave E, G3 200, Seattle, WA 98109 1023, USA
    Radiology 244:381-8. 2007
    ..To prospectively determine cancer yield, callback and biopsy rates, and positive predictive value (PPV) of mammography, magnetic resonance (MR) imaging, and ultrasonography (US) in women at high risk for breast cancer...
  19. ncbi Osteopontin as an adjunct to CA125 in detecting recurrent ovarian cancer
    John O Schorge
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Texas Southwestern Medical School, Dallas, Texas 75390, USA
    Clin Cancer Res 10:3474-8. 2004
    ..The purpose of this study was to test the hypothesis that OPN is a clinically useful adjunct to CA125 in detecting recurrent ovarian cancer...